Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment for people suffering from neurohealth conditions. In addition to selling the NeuroStar system and associated treatment sessions to customers, it operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or TMS) and Spravato (esketamine nasal spray) for the treatment of major depressive disorder (MDD) and other mental health disorders. NeuroStar Advanced Therapy is the TMS treatment for MDD in adults. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. It provides more than 1.68 million treatments to over 51,000 patients struggling with depression.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 74.89Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 17.62です。
適正水準
同社の最新のPEは-2.57で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は47.56M株で、前四半期比で7.81%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を2.74M株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.95です。